Expression of ADAM12 is regulated by E2F1 in small cell lung cancer

Li,Zunling; Wang,Yaopeng; Kong,Lijun; Yue,Zhen; Ma,Ying; Chen,Xufang

doi:10.3892/or.2015.4317

Expression of ADAM12 is regulated by E2F1 in small cell lung cancer

Authors:
- Zunling Li
- Yaopeng Wang
- Lijun Kong
- Zhen Yue
- Ying Ma
- Xufang Chen
View Affiliations

Affiliations: Department of Biochemistry and Molecular Biology, Binzhou Medical University, Yantai, Shandong 264003, P.R. China, Department of Thoracic Surgery, Affiliated Hospital of Qingdao University, Qingdao, Shandong 266071, P.R. China, Department of Oncology, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, Shandong 264199, P.R. China
Published online on: October 1, 2015 https://doi.org/10.3892/or.2015.4317
Pages: 3231-3237

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Our previous study reported that ADAM12 was highly expressed in small cell lung cancer (SCLC) and could be an effective marker for diagnosis and prognosis. Yet, the reason for the high expression of ADAM12 in SCLC requires further elucidation. Transcription factor E2F1 has been receiving increasing attention due to the complexity and diversity of its function in cancer. In the present study, the expression of ADAM12 was significantly decreased following silencing of E2F1 expression by siRNA, thus indicating that E2F1 may regulate the expression of ADAM12 at the level of transcription. Chromatin immunoprecipitation-to-sequence analysis identified three binding sites for E2F1 in the locus for ADAM12. They were Chr10: 128010444-128011026, located in the intron of ADAM12, named seq0; Chr10: 128076927‑128078127, located in the promoter of ADAM12, named seq1; and Chr10: 128086195‑128086876, located in the upstream 20 kb from the transcription start site of ADAM12, named: seq2. Dual‑luciferase reporter experiments revealed that seq1 not seq0 and seq2 was able to promote the expression of luciferase. Notably, co-transfection of E2F1 significantly increased the activity of seq1 not seq0 and seq2, but quantitative polymerase chain reaction results showed that seq0, seq1 and seq2 could recruit E2F1, indicating that the influence of E2F1 in regulating the expression of ADAM12 was complex. Sequence analysis clarified that seq1 was a part of the ADAM12 promoter, yet the functions of seq0 and seq2 were unknown. Fusion fragments containing seq0-seq1 or seq2-seq1 were analyzed in luciferase constructs. Compared with seq1 alone, the activities of these fusion fragments were non-significantly reduced. The activities of fusion fragments were significantly decreased following co-transfection with E2F1. Thus, the present findings support the conclusion that the E2F1 transcription factor regulates the expression of ADAM12 by binding differential cis-acting elements.

View Figures

View References

1	Mazzocca A, Giannelli G and Antonaci S: Involvement of ADAMs in tumorigenesis and progression of hepatocellular carcinoma: Is it merely fortuitous or a real pathogenic link? Biochim Biophys Acta. 1806:74–81. 2010.PubMed/NCBI
2	Jacobsen J, Visse R, Sørensen HP, Enghild JJ, Brew K, Wewer UM and Nagase H: Catalytic properties of ADAM12 and its domain deletion mutants. Biochemistry. 47:537–547. 2008. View Article : Google Scholar
3	Ieguchi K, Tomita T, Omori T, Komatsu A, Deguchi A, Masuda J, Duffy SL, Coulthard MG, Boyd A and Maru Y: ADAM12-cleaved ephrin-A1 contributes to lung metastasis. Oncogene. 33:2179–2190. 2014. View Article : Google Scholar
4	Kerna I, Kisand K, Suutre S, Murde M and Tamm A, Kumm J and Tamm A: The ADAM12 is upregulated in synovitis and postin-flammatory fibrosis of the synovial membrane in patients with early radiographic osteoarthritis. Joint Bone Spine. 81:51–56. 2014. View Article : Google Scholar
5	Higashiyama S: Membrane-anchored heparin-binding EGF-like growth factor processing by ADAM12 in cardiac hypertrophy. Nihon Rinsho. 61:767–775. 2003.In Japanese. PubMed/NCBI
6	Roy R, Rodig S, Bielenberg D, Zurakowski D and Moses MA: ADAM12 transmembrane and secreted isoforms promote breast tumor growth: A distinct role for ADAM12-S protein in tumor metastasis. J Biol Chem. 286:20758–20768. 2011. View Article : Google Scholar : PubMed/NCBI
7	Peduto L, Reuter VE, Sehara-Fujisawa A, Shaffer DR, Scher HI and Blobel CP: ADAM12 is highly expressed in carcinoma-associated stroma and is required for mouse prostate tumor progression. Oncogene. 25:5462–5466. 2006. View Article : Google Scholar : PubMed/NCBI
8	Shao S, Li Z, Gao W, Yu G, Liu D and Pan F: ADAM-12 as a diagnostic marker for the proliferation, migration and invasion in patients with small cell lung cancer. PLoS One. 9:e859362014. View Article : Google Scholar : PubMed/NCBI
9	Le Pabic H, Bonnier D, Wewer UM, Coutand A, Musso O, Baffet G, Clément B and Théret N: ADAM12 in human liver cancers: TGF-beta-regulated expression in stellate cells is associated with matrix remodeling. Hepatology. 37:1056–1066. 2003. View Article : Google Scholar : PubMed/NCBI
10	Ray BK, Dhar S, Shakya A and Ray A: Z-DNA-forming silencer in the first exon regulates human ADAM-12 gene expression. Proc Natl Acad Sci USA. 108:103–108. 2011. View Article : Google Scholar :
11	Li H, Solomon E, Duhachek Muggy S, Sun D and Zolkiewska A: Metalloprotease-disintegrin ADAM12 expression is regulated by Notch signaling via microRNA-29. J Biol Chem. 286:21500–21510. 2011. View Article : Google Scholar : PubMed/NCBI
12	Díaz B, Yuen A, Iizuka S, Higashiyama S and Courtneidge SA: Notch increases the shedding of HB-EGF by ADAM12 to poten-tiate invadopodia formation in hypoxia. J Cell Biol. 201:279–292. 2013. View Article : Google Scholar
13	Li Z, Guo Y, Jiang H, Zhang T, Jin C, Young CY and Yuan H: Differential regulation of MMPs by E2F1, Sp1 and NF-kappa B controls the small cell lung cancer invasive phenotype. BMC Cancer. 14:2762014. View Article : Google Scholar : PubMed/NCBI
14	Ioannou M, Papamichali R, Kouvaras E, Mylonis I, Vageli D, Kerenidou T, Barbanis S, Daponte A, Simos G, Gourgoulianis K, et al: Hypoxia inducible factor-1 alpha and vascular endothelial growth factor in biopsies of small cell lung carcinoma. Lung. 187:321–329. 2009. View Article : Google Scholar : PubMed/NCBI
15	Harris HA, Murrills RJ and Komm BS: Expression of meltrin-alpha mRNA is not restricted to fusagenic cells. J Cell Biochem. 67:136–142. 1997. View Article : Google Scholar : PubMed/NCBI
16	Kurisaki T, Masuda A, Osumi N, Nabeshima Y and Fujisawa-Sehara A: Spatially- and temporally-restricted expression of meltrin alpha (ADAM12) and beta (ADAM19) in mouse embryo. Mech Dev. 73:211–215. 1998. View Article : Google Scholar : PubMed/NCBI
17	Borneman A, Kuschel R and Fujisawa-Sehara A: Analysis for transcript expression of meltrin alpha in normal, regenerating, and denervated rat muscle. J Muscle Res Cell Motil. 21:475–480. 2000. View Article : Google Scholar : PubMed/NCBI
18	Galliano MF, Huet C, Frygelius J, Polgren A, Wewer UM and Engvall E: Binding of ADAM12, a marker of skeletal muscle regeneration, to the muscle-specific actin-binding protein, alpha -actinin-2, is required for myoblast fusion. J Biol Chem. 275:13933–13939. 2000. View Article : Google Scholar : PubMed/NCBI
19	Cao Y, Zhao Z, Gruszczynska-Biegala J and Zolkiewska A: Role of metalloprotease disintegrin ADAM12 in determination of quiescent reserve cells during myogenic differentiation in vitro. Mol Cell Biol. 23:6725–6738. 2003. View Article : Google Scholar : PubMed/NCBI
20	Abe E, Mocharla H, Yamate T, Taguchi Y and Manolagas SC: Meltrin-alpha, a fusion protein involved in multinucleated giant cell and osteoclast formation. Calcif Tissue Int. 64:508–515. 1999. View Article : Google Scholar : PubMed/NCBI
21	Verrier S, Hogan A, McKie N and Horton M: ADAM gene expression and regulation during human osteoclast formation. Bone. 35:34–46. 2004. View Article : Google Scholar : PubMed/NCBI
22	Wu C, Li L, Zhao J, Fan Q, Tian WX and He RQ: Effect of α₂M on earthworm fibrinolytic enzyme III-1 from Lumbricus rubellus. Int J Biol Macromol. 31:71–77. 2002. View Article : Google Scholar
23	Gilpin BJ, Loechel F, Mattei MG, Engvall E, Albrechtsen R and Wewer UM: A novel, secreted form of human ADAM 12 (meltrin alpha) provokes myogenesis in vivo. J Biol Chem. 273:157–166. 1998. View Article : Google Scholar : PubMed/NCBI
24	Tani N, Higashiyama S, Kawaguchi N, Madarame J, Ota I, Ito Y, Ohoka Y, Shiosaka S, Takada Y and Matsuura N: Expression level of integrin alpha 5 on tumour cells affects the rate of metastasis to the kidney. Br J Cancer. 88:327–333. 2003. View Article : Google Scholar : PubMed/NCBI
25	Kveiborg M, Albrechtsen R, Rudkjaer L, Wen G, Damgaard-Pedersen K and Wewer UM: ADAM12-S stimulates bone growth in transgenic mice by modulating chondrocyte proliferation and maturation. J Bone Miner Res. 21:1288–1296. 2006. View Article : Google Scholar : PubMed/NCBI
26	Bourd-Boittin K, Le Pabic H, Bonnier D, L'Helgoualc'h A and Théret N: RACK1, a new ADAM12 interacting protein. Contribution to liver fibrogenesis. J Biol Chem. 283:26000–26009. 2008. View Article : Google Scholar : PubMed/NCBI
27	Wyllie AH: E2F1 selects tumour cells for both life and death. J Pathol. 198:139–141. 2002. View Article : Google Scholar : PubMed/NCBI
28	Johnson JL, Pillai S, Pernazza D, Sebti SM, Lawrence NJ and Chellappan SP: Regulation of matrix metalloproteinase genes by E2F transcription factors: Rb-Raf-1 interaction as a novel target for metastatic disease. Cancer Res. 72:516–526. 2012. View Article : Google Scholar :
29	Ji W, Zhang W and Xiao W: E2F-1 directly regulates thrombos-pondin 1 expression. PLoS One. 5:e134422010. View Article : Google Scholar
30	Minato Y, Tashiro E, Kanai M, Nihei Y, Kodama Y and Imoto M: Transcriptional regulation of a new variant of human platelet-derived growth factor receptor alpha transcript by E2F-1. Gene. 403:89–97. 2007. View Article : Google Scholar : PubMed/NCBI
31	Pillai S, Kovacs M and Chellappan S: Regulation of vascular endothelial growth factor receptors by Rb and E2F1: Role of acetylation. Cancer Res. 70:4931–4940. 2010. View Article : Google Scholar : PubMed/NCBI
32	Lavrrar JL and Farnham PJ: The use of transient chromatin immunoprecipitation assays to test models for E2F1-specific transcriptional activation. J Biol Chem. 279:46343–46349. 2004. View Article : Google Scholar : PubMed/NCBI
33	Jin VX, Rabinovich A, Squazzo SL, Green R and Farnham PJ: A computational genomics approach to identify cis-regulatory modules from chromatin immunoprecipitation microarray data - a case study using E2F1. Genome Res. 16:1585–1595. 2006. View Article : Google Scholar : PubMed/NCBI
34	Weinmann AS, Bartley SM, Zhang T, Zhang MQ and Farnham PJ: Use of chromatin immunoprecipitation to clone novel E2F target promoters. Mol Cell Biol. 21:6820–6832. 2001. View Article : Google Scholar : PubMed/NCBI
35	Wells J, Graveel CR, Bartley SM, Madore SJ and Farnham PJ: The identification of E2F1-specific target genes. Proc Natl Acad Sci USA. 99:3890–3895. 2002. View Article : Google Scholar : PubMed/NCBI